Mr. Paul Steckler serves as Chief Commercial Officer at Shield Therapeutics plc. Mr. Steckler served as a Vice President of Commercial Operations at Shield Holdings AG since September 11, 2015. Mr. Steckler is a commercial leader with more than 17 years of Pharmaceutical experience across a broad range of therapeutic areas. He spent the majority of his career at Pfizer working across multiple therapy areas including Genotropin, Somavert, Zyvoz, Vfend, Ecalta, Rapamune and Tygacil. He successfully reinvigorated the speciality portfolio returning the brands to growth in excess of 14%. Since leaving Pfizer in 2012, he has worked with a number of smaller pharmaceutical companies with a focus on speciality medications including launching Jinarc (in polycystic kidney disease) for Otsuka Pharmaceuticals. All of this experience is utilised to ensure commercial plans are fit for purpose and focused on achieving the best return for current and future assets. He joined the pharmaceutical industry in 1997. Mr. Steckler gained a BSc in Microbiology & Virology from Warwick University.

 Microbiology & Virology